Immunovia is a capital-efficient company targeting the huge unmet need in early pancreatic cancer detection. We will launch our highly accurate PancreaSure test in the U.S. in Q3 2025 to drive commercial success and create shareholder value.
Watch the recorded presentation by Jeff Borcherding from Aktiedagarna in Stockholm.
Immunovia’s executive team has blended scientific, clinical and commercial expertise to build the leading company in early detection of pancreatic cancer. They learned best practices at many of the would top life science companies and learned to move quickly and operate efficiently at high-growth early stage companies.
Immunovia has assembled a diverse and cohesive board with expertise in multiple areas to successfully guide the company through both test development and commercialization.